Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401193 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of XP12B in Women With Menorrhagia
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT00401193: Completed Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT00401193 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 304 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00401193, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
Primary Outcome
reduction of menstrual blood loss in mL
Interventions
- DRUG Tranexamic acid tablets
- DRUG Placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00401193 record still lists
NCT00401193 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Tranexamic acid tablets is the first listed.
NCT00401193 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00401193 about?
NCT00401193 is a clinical study titled "Efficacy and Safety of XP12B in Women With Menorrhagia". The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
What is the current status of trial NCT00401193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2006-11. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00401193?
The interventions under investigation include: Tranexamic acid tablets (DRUG), Placebo tablets (DRUG).
Who is sponsoring clinical trial NCT00401193?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00401193's enrollment target sits among peer trials
304 1117th of 2000 higher than 882 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia